Business
The economics of cruises

The largest cruise company in the world is back in the black, but profit margins aren’t quite what they used to be

On Monday, the world’s largest cruise company, Carnival Corp., announced that it’s retiring one of its flagship enterprises — P&O Cruises Australia — and folding it into the wider Carnival Cruises brand.

The boats that rocked

Carnival said the move should help further optimize “the company's brand portfolio creating operational efficiencies”... which is just the kind of corporate jargon that investors love. In turn, the company’s shares rose 6% yesterday amidst a strong day for cruise stocks in general — an industry that, after nearly collapsing 4 years ago, has sailed back into profitable territory and is seeking to cut costs wherever it can.

Indeed, 2023 was the first fiscal year since the pandemic that Carnival Corp. reported an operating profit (~$2B), after accruing cumulative operating losses of more than $20B between 2020-2022. So, if you were one of Carnival’s 12.5 million passengers last year, where exactly did your money go?

The economics of a cruise

Per company filings, the average ticket in 2023 would have cost about $1,125. But your wallet doesn’t get off that lightly, with Carnival banking another $600 or so per customer on top of that thanks to excursions, food, drinks, casino games, retail sales, spa treatments, laundry services, internet access, and other onboard concessions.

Actually operating the cruise and tours cost the company $1,145 in our example, leaving a healthy $582 left to cover overheads. Of course, one major cost we’ve ignored until now is the ships themselves. That shows up predominantly in “depreciation”, with the company spreading the cost of its ships over a 30-year lifespan. So, what’s Carnival left with? About $150 out of the original $1,700, or a 9% margin. Company execs will be hoping that cutting less profitable routes will get it back to the 15-16% margins that were common pre-pandemic.

More Business

See all Business
Strive Pharmacy recently broke ground on a new facility in Mesa, Arizona. (Strive Pharmacy)

Before Hims’ GLP-1 pill fallout, its pharmacy partner was already drawing scrutiny from state regulators

Strive has already been probed over the timing of its GLP-1 compounding. Now, Arizona regulators are looking into complaints about ketamine misuse and improper distribution of prescription drugs.

business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.